Abstract
The third generation β-blockers possess important ancillary properties besides inhibiting β-adrenoceptors. Among them, nebivolol activates nitric oxide synthase (NOS). Nebivolol and carvedilol preserve NOS activity by reducing asymmetrical dimethylarginine (AMDA) and enhance the bioavailability of nitric oxide (NO) because of their antioxidant properties. Concerning the treatment of hypertension and chronic heart failure, these third generation β-blockers show distinct advantages resulting from their NO-dependent effects (vasodilatation, anti-proliferation and cardioprotection), which may translate into a more effective clinical outcome than that obtained with the conventional β-blockers. Impaired NOS activity and reduced NO bioavailability are common initiators of cardiovascular dysfunction. Thus, owing to their NO-mediated actions, the new generation β-blockers should find more clinical applications in the treatment of cardiovascular diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
